tbuckley/cabot-search huggingface dataset:
Abstract 5588: Nevus count and dermoscopic pattern associated with MC1R RHC-variant alleles in a case-control study of melanoma
Authors: Phil McClenahan, Kasturee Jagirdar, Katie Lee, Elizabeth McEniery, Sam Beh, Brian Burke, David L. Duffy, H. Peter Soyer, Richard A. Sturm
Journal: Cancer Research (2015)

Abstract The total number of acquired melanocytic nevi (TNC) is the strongest known risk factor for cutaneous malignant melanoma (CMM). An increased risk of CMM is also seen with individuals with red hair, fair skin and poor tanning ability (RHC phenotype); and who carry variant alleles of the MC1R gene designated as R. High freckling scores but reduced nevus counts have been reported in individuals with the RHC phenotype. The relationship between these reciprocal phenotypes of lower vs higher nevus counts, both with increased risk of CMM, is complex and supports hypotheses of different pathways to melanoma formation. We have reported on a case-control study of nevi in volunteers from the South-east Queensland area combining an assessment of pigmentation characteristics, nevus phenotype including dermoscopic nevus subtypes with genotypic comparisons and melanoma risk for 573 individuals. This sample set has been further examined to delineate the nevus characteristics of 46 individuals who are homozygous MC1R RHC allele carriers R/R. We wished to determine if there is any commonality in the pigmentation or melanocytic nevus phenotype including number, size, distribution, profile and colour that may distinguish these patients. Body mass index (BMI), body surface area (BSA), TNC and MC1R genotype were analysed and found that participants with personal melanoma history had higher TNC (P&amp;lt;0.005). We found no association between MC1R genotype and BMI but there exists a weak association between BSA and higher TNC. Within the MC1R R/R cohort, melanoma patients are more likely to have high TNC than controls (P&amp;lt;0.01). The signature dermoscopic pattern for the individuals in the MC1R R/R group is at increased odds of being a non-specific pattern (P&amp;lt;0.01). A significant difference in MC1R R/R TNC dependent on melanoma history exists and there is a predisposition towards a non-specific signature nevus pattern. Citation Format: Phil McClenahan, Kasturee Jagirdar, Katie Lee, Elizabeth McEniery, Sam Beh, Brian Burke, David L. Duffy, H. Peter Soyer, Richard A. Sturm. Nevus count and dermoscopic pattern associated with MC1R RHC-variant alleles in a case-control study of melanoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5588. doi:10.1158/1538-7445.AM2015-5588
Case 82-1962
Authors: George P. Baker, Austin L. Vickery
Journal: New England Journal of Medicine (1962)

Presentation of Case First admission. A fifty-year-old woman was referred to the hospital for treatment of gangrene of the right foot.Two weeks before admission, after she had pared a callus, the base of the second toe of the right foot became painful, purple and swollen, with the discoloration extending over the dorsum of the foot. Hot soaks and penicillin were given, but the base of the toe became ulcerated. A urinalysis was said to show sugar. The patient had not noticed loss of weight, polydipsia, polyuria, pruritus or changes in sensation in the extremities. Urinalyses done several years previously . . .
Abstract 29: Concordance of somatic mutations found in primary tumors and plasma circulating-free DNA from early and late-stage colorectal cancer patients
Authors: Steven M. Bray, Philip J. Ebert, John N. Calley, Richard E. Higgs, Isabella H. Wulur, Swee Seong Wong, Candice L. Horn, Ricardo Martinez, Christoph Reinhard
Journal: Clinical Cancer Research (2016)

Abstract Circulating-free DNA (cfDNA) holds great potential for non-invasive somatic mutation detection in cancer patients as a so-called “liquid biopsy”. A liquid biopsy is especially valuable when tumor tissue is not available and for longitudinal monitoring of tumor burden or emerging resistance. In such cases, tumor-specific mutations are not known a priori and in order to detect tumor-derived somatic mutations it is best to interrogate a broad panel of cancer genes. The primary obstacle to sequencing cfDNA with broad mutation panels is achieving the necessary limit of detection to identify small amounts of tumor-derived cfDNA relative to the predominant wild-type cfDNA in the plasma of cancer patients. Tumor-derived cfDNA levels correlate with tumor stage, also making it an important consideration when investigating the sensitivity of this approach. We demonstrate the detection of somatic variants in several cancer genes in the plasma of early and late-stage colorectal cancer (CRC) patients by deep sequencing (&amp;gt; 8,000X) the cfDNA and matched normal DNA of N=33 CRC patients using the AmpliSeq cancer panel. The AmpliSeq panel requires less than 10ng of input DNA and amplifies hotspot loci of 50 known cancer genes for next-generation sequencing (NGS). We observe at least one somatic mutation with greater than 0.1% variant allele frequency in the cfDNA of all 33 CRC patients. We also show the sensitivity of detecting tumor-derived somatic mutations in cfDNA by exome sequencing of the primary tumor tissue. We find higher sensitivity for tumor mutations in cfDNA of late-stage patients compared to early-stage patients. Overall, we demonstrate the feasibility of using NGS on a small sized cancer panel for identifying somatic mutations, including those with low variant allele frequency, in cfDNA of early and late-stage CRC patients. Although a cfDNA approach holds promise as a tool to aid in pre-clinical and clinical research, more work is needed to understand its performance under different assay and disease conditions. Citation Format: Steven M. Bray, Philip J. Ebert, John N. Calley, Richard E. Higgs, Isabella H. Wulur, Swee Seong Wong, Candice L. Horn, Ricardo Martinez, Christoph Reinhard. Concordance of somatic mutations found in primary tumors and plasma circulating-free DNA from early and late-stage colorectal cancer patients. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(1_Suppl):Abstract nr 29.
TCTAP A-052 Medium Term Target Lesion Failure in Patient Treated with Bioresorbable Vascular Scaffold
Authors: Michael Mao-Chen Liang, Takashi Kajiya, Ronald Chi-Hang Lee, Mark Chan, Edgar Lik-Wui Tay, Koo Hui Chan, Joshua P. Loh, Poay-Huan Loh, Huay Cheem Tan, Adrian Low
Journal: Journal of the American College of Cardiology (2016)
Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia
Authors: Gurvaneet S. Randhawa, Hengmi Cui, Janet A. Barletta, Liora Z. Strichman-Almashanu, Moshe Talpaz, Hagop Kantarjian, Albert B. Deisseroth, Richard C. Champlin, Andrew P. Feinberg
Journal: Blood (1998)
Deficient Transcription of Mouse Mast Cell Protease 4 Gene in Mutant Mice of mi/mi Genotype
Authors: Tomoko Jippo, Young-Mi Lee, Yee Katsu, Kumiko Tsujino, Eiichi Morii, Dae-Ki Kim, Hyung-Min Kim, Yukihiko Kitamura
Journal: Blood (1999)
Cellular Composition During Tumor Induction in Rats by Cycad Husk
Authors: Cornelia Hoch-Ligeti, Ernest Stutzman, Joan M. Arvin
Journal: JNCI Journal of the National Cancer Institute (1968)

Rats fed a diet containing 5 or 10% fresh or dried husk of the cycad nut (Cycas circinalis) developed, after about 200 days, clear cell and papillary carcinomas, sarcomas, and Wilms' tumors in the kidneys. In the liver, widespread cystic cholangiomas and a few hepatomas were present. Rats fed 2½ and 10% zamia (Zamia debilis) leaves for over 1 year did not develop tumors even after 2 years. During carcinogenesis and in tumor-bearing rats the DNA and RNA concentrations of liver and kidney homogenates and nuclei, the nuclear nitrogen content, and the concentrations of a mitochondrial (succinic dehydrogenase) and of a lysosomal enzyme (β-glucuronidase) were investigated. In the tumor-bearing rats the DNA and RNA contents of the nuclei were increased in the liver, which contained numerous disseminated small hepatomas and cholangiomas. The DNA, nuclear RNA, nitrogen, and β-glucuronidase concentrations were significantly increased in kidney tumors but not in the uninvolved kidney tissue. The succinic dehydrogenase concentration in the kidneys of the tumor-bearing rats and in the kidney tumors was significantly decreased. The β-glucuronidase concentration was significantly increased in the livers during feeding of cycad husk, but not after the feeding was terminated. This initial change in the β-glucuronidase concentration of liver, when husk is fed, is considered to be connected with detoxification and is independent of the carcinogenic activity.
Case 15-2004: Cancer Therapy and Sperm Banking
Authors: John K Amory
Journal: New England Journal of Medicine (2004)

the authors reply: Drs.Steiger and Turowski make an important point regarding the association between fibromuscular dysplasia and intracranial aneurysms, for which the prevalence has been reported to be as high as 51 percent. 1,2However, the prevalence estimates may be falsely elevated because of selection bias; many of the patients with aneurysms in these series underwent angiography after presenting with subarachnoid hemorrhage.Fibromuscular dysplasia was an incidental finding in some of the reported cases. 3hen patients who presented with subarachnoid hemorrhage are excluded from the prevalence estimates, the prevalence of incidental, asymptomatic cerebral aneurysms in patients with internal-carotid-artery or vertebral-artery fibromuscular dysplasia is only 7.3 percent. 3By comparison, a meta-analysis of 23 studies (with a total of 56,304 patients) showed a prevalence of intracranial aneurysms of 0.4 percent in retrospective autopsy series, 3.6 percent in prospective autopsy series, 3.7 percent in retrospective angiography studies, and 6.0 percent in prospective angiography studies; the annual risk of rupture was 0.7 percent.
Risk of Childhood Cancer by Maternal Birthplace
Authors: Julia E. Heck, Andrew S. Park, Zuelma A. Contreras, Tom B. Davidson, Katherine J. Hoggatt, Myles Cockburn, Beate Ritz
Journal: JAMA Pediatrics (2016)

<h3>Importance</h3> The<i>Hispanic epidemiologic paradox</i>is the phenomenon that non-US–born Hispanic mothers who immigrate to the United States have better pregnancy outcomes than their US-born counterparts. It is unknown whether this advantage extends to childhood cancer risk. <h3>Objective</h3> To determine whether the risk for childhood cancers among Hispanic children varies by maternal birthplace. <h3>Design, Setting, and Participants</h3> In this population-based case-control study conducted in June 2015, cohort members were identified through California birth records of children born in California from January 1, 1983, to December 31, 2011. Information on cancer diagnoses was obtained from California Cancer Registry records from 1988 to 2012. Cases (n = 13 666) were identified from among children younger than 6 years in the California Cancer Registry and matched to California birth certificates. Control children (n = 15 513 718) included all other children born in California during the same period. Maternal birthplace and ethnic ancestry were identified from the birth certificate. <h3>Main Exposures</h3> Maternal race/ethnicity and birthplace. <h3>Main Outcomes and Measures</h3> We used Cox proportional hazards modeling to estimate hazard ratios (HRs) of childhood cancer. <h3>Results</h3> Included in the study were 4 246 295 children of non-Hispanic white mothers (51.3% male), 2 548 822 children of US-born Hispanic mothers (51.0% male), and 4 397 703 children of non-US–born Hispanic mothers (51.0% male). Compared with children of non-Hispanic white mothers, the children of non-US–born Hispanic mothers had a reduced risk for glioma (HR, 0.50; 95% CI, 0.44-0.58), astrocytoma (HR, 0.43; 95% CI, 0.36-0.51), neuroblastoma (HR, 0.47; 95% CI, 0.40-0.54), and Wilms tumor (HR, 0.70; 95% CI, 0.59-0.82). For these cancer types, the risk estimates for children of US-born Hispanic mothers fell between those of the children of US-born white and non-US–born Hispanic mothers. Children of Mexican-born mothers had a higher risk of yolk sac tumors (HR, 1.46; 95% CI, 0.99-2.17), while children of US-born Hispanic mothers with ancestry from countries other than Mexico had a higher risk for unilateral retinoblastoma (HR, 2.03; 95% CI, 1.33-3.11). <h3>Conclusions and Relevance</h3> For several cancers, we observed differential risk by maternal place of birth. Examining the differences in health behaviors and environment between Hispanic groups may shed light on childhood cancer etiology.
Small differences, big implications.
Authors: I C Henderson
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.8.1297 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2199617 Small differences, big implications. I C HendersonxI C HendersonSearch for articles by this author Show More Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. https://doi.org/10.1200/JCO.1990.8.8.1297 First Page PDF © 1990 by American Society of Clinical Oncology
Yoga may improve asthma symptoms, Cochrane review finds
Authors: Jacqui Wise
Journal: BMJ (2016)

A Cochrane review has concluded that yoga “probably” improves quality of life and symptoms in people who have asthma. However, its effects on lung function and the use of medicines remain uncertain.

The Cochrane researchers found 15 randomised controlled trials that looked at yoga and asthma, including 1048 men and women in total.1 Most of the trials were conducted in India, Europe, or the United States. Most of the participants had mild to moderate asthma lasting …
Lithium, benzodiazepines, and sexual function in bipolar patients
Authors: A M Ghadirian, L Annable, M C Bélanger
Journal: American Journal of Psychiatry (1992)

Lithium and benzodiazepines are widely used in the treatment of bipolar patients. Yet studies of the effect of these drugs on sexual function are scarce. This study surveyed sexual function in bipolar patients treated with lithium, either alone or in combination with other drugs.Sexual function was assessed by self-rating scale in 104 outpatients (45 men and 59 women) with a DSM-III diagnosis of bipolar disorder who were attending an affective disorders clinic. All patients were under treatment with lithium, either alone (35%) or in combination with benzodiazepines (49%), tricyclic antidepressants (17%), neuroleptics (17%), tryptophan (10%), or carbamazepine (1%). The patients were in a stable and euthyroid state at the time of the assessment. Serum lithium and plasma prolactin concentrations were measured at the same time.Multiple regression analysis revealed an association between concomitant benzodiazepine administration and sexual dysfunction scores. Difficulties in sexual functioning were significantly more common in patients treated with a combination of lithium and benzodiazepines (49%) than in those treated with either lithium alone (14%) or lithium in combination with other drugs (17%). No relationship was found between serum lithium or plasma prolactin levels and sexual dysfunction scores.Lithium, when given alone, did not appear to have a major effect on sexual function, whereas its combination with benzodiazepines was associated with sexual dysfunction in about half of the patients. More attention should be given to drug-induced sexual dysfunction, since its presence can have important consequences for clinical management and compliance.
Cancer therapy with immature monocyte-derived dendritic cells in patients with advanced breast cancer
Authors: T. Nesselhut, C. Matthes, D. Marx, R. Y. Chang, J. Nesselhut, N. Cillien, D. R. Lorenzen, R. Gorter, W. Stücker, J. H. Peters
Journal: Journal of Clinical Oncology (2005)

2528 Background: Recent studies have shown that immunotherapy with monocyte-derived dendritic cells can induce clinical antitumor response in various types of solid tumors. Methods: After isolating monocytes from the peripheral blood of n=143 patients with advanced breast cancer, immature dendritic cells (iMoDC) were generated ex vivo in the presence of IL-4, GM-CSF and autologous serum. The iMoDC loaded with tumor cell lysate, known peptides or with tumor proteins from autologous serum were administered to patients intradermally or intravenously. Using flow cytometry and fluorescence microscopy, the phagocytic activity and surface markers on the iMoDC and on tumor cells of select treated patients were investigated. Results: MoDC vaccination induced a clinical response in n=56 (37%) patients producing 7 complete remissions, 14 partial or minor remissions, 33 stable diseases and 3 mixed responses with a median overall survival after onset of the MoDC-therapy of 25 months (2–59 months) and a 3-years survival rate of 16%. On the other hand, no response was observed in n=87 patients with a median survival of 4 months (1–39 months) and a 3-years survival rate of 1%. None of the studied cases show a complete down regulation of either MHC-I/II or ICAM-1 and LFA-3. The percentages of positive cells differed from patient to patient. Phagocytosis assay demonstrated that iMoDC from patients with advanced breast cancer are able to phagocytose soluble tumor proteins. Certain culture conditions promoted a phenotype of the iMoDC from breast cancer patients similar to the iMoDC from healthy controls. Addition of IFN-alpha resulted in an up regulation of the co-stimulatory molecules CD80 and CD86 without loss of phagocytic activity. Conclusions: We show that dendritic cell based immunotherapy can produce durable tumor response even in advanced breast cancer. The heterogeneous expression of immunological relevant molecules on tumor cells may lead to clonal selection of cells refractory to dendritic therapy. As iMoDC from breast cancer patients are able to phagocytose soluble tumor proteins, our results suggest that immature dendritic cells could either uptake tumor antigens in vivo or be loaded by soluble tumor antigens ex vivo. No significant financial relationships to disclose.
TCTAP A-034 Endovascular Treatment in the Complicated Type B Aortic Dissection and Malperfusion Syndrome
Authors: Bo Won Kim, Han Cheol Lee, Jong Hyun Choi, Jin Sup Park, Hye Won Lee, Jun-Hyok Oh, Kwang Soo Cha, Taek Jong Hong
Journal: Journal of the American College of Cardiology (2016)
Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
Authors: Kathleen N. Moore, Lainie P. Martin, Shelly Marie Seward, Todd Michael Bauer, David M. O'Malley, Raymond P. Perez, Amit M. Oza, Woondong Jeong, Maurice William Kirby, Yinghui Zhou, Mary F. Michenzie, Joseph Ponte, Rodrigo Ruiz-Soto, Michael J. Birrer
Journal: Journal of Clinical Oncology (2015)

5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-binding antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of IMGN853 in pts with FRα-positive solid tumors. A recommended phase II dose (RP2D) of 6.0 mg/kg, administered once every three weeks using adjusted ideal body weight was established in the dose-finding phase. Preliminary evidence of antitumor activity is being investigated at the RP2D in disease-specific cohorts of pts with platinum-resistant EOC and relapsed/refractory endometrial carcinoma. Here we report preliminary clinical activity (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) at the RP2D in pts with platinum-resistant EOC. Results: To date, 14 platinum-resistant EOC pts have been treated at the RP2D: 2 in dose escalation; 12 in the expansion cohort. All pts were heavily pretreated (mean: 4.5; range 2-12 prior treatments), all had prior taxane exposure, and all had progressed on their most recent regimen. All pts had FRα-positive tumor expression by IHC in archival tissue. Clinical benefit was observed in 5 /10 evaluable patients (4 have not reached 1st assessment): 4 PRs and 1 confirmed CA125 response, for an objective response rate (ORR) of 40% and clinical benefit rate (CBR) of 50%. In each pt with a PR, tumor regression had begun early on treatment (cycle 2 evaluation). Shrinkage of visceral metastases was seen: a PR pt had a 45% reduction in a 5 cm liver mass. One additional pt had an unconventional response: the disappearance of a non-target lesion with development of new lesions. The majority of adverse events (AEs) were CTCAE grade 1 or 2, with diarrhea, ocular events, cough, fatigue, decreased appetite, neuropathy and nausea reported in > 20 % of pts. Nine of the 14 pts remain on study; enrollment continues. Conclusions: IMGN853 demonstrates promising preliminary clinical activity with an ORR of 40% and CBR of 50%, in heavily pretreated platinum-resistant ovarian cancer pts with a manageable AE profile. Clinical trial information: NCT01609556.
TCTAP A-127 Different Clinical Impact Between Angiotensin-Converting Enzyme Inhibitors and AT1 Receptor Blockers: A Nationwide Cohort Study
Authors: Chun-Yuan Chu, Wen-Hsien Lee, Po-Chao Hsu, Ho-Ming Su, Hung-Hao Lee, Cheng-An Chiu, Tsung-Hsien Lin, Chee-Siong Lee, Heueh-Wei Yen, Wen-Chol Voon, Wen-Ter Lai, Sheng-Hsiung Sheu
Journal: Journal of the American College of Cardiology (2016)
Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in vivo
Authors: K Imada, A Takaori-Kondo, T Akagi, K Shimotohno, K Sugamura, T Hattori, H Yamabe, M Okuma, T Uchiyama
Journal: Blood (1995)
Abstract 915: A Novel Missense Mutation in Cardiac Ryanodine Receptor Gene as a Possible Cause of Hypertrophic Cardiomyopathy: Evidence From Familial Analysis
Authors: Noboru Fujino, Hidekazu Ino, Kenshi Hayashi, Katsuharu Uchiyama, Mitsuru Nagata, Tetsuo Konno, Hiromasa Katoh, Yuichiro Sakamoto, Toshinari Tsubokawa, Kazuo Ohsato, Sumio Mizuno, Masakazu Yamagishi
Journal: Circulation (2006)